Concepedia

Virangika K. Wimalasena

VK

5

Publications

286

Citations

5

H-Index

2019

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

University of Oxford

Virangika K. Wimalasena is an author at Dana-Farber Cancer Institute specializing in immunology, cell biology, and cancer research.

ORCID

Top concepts

Publications per year

2019–2022

5

Publications

5

EP300 Selectively Controls the Enhancer Landscape of <i>MYCN</i> -Amplified Neuroblastoma

Adam D. Durbin, Tingjian Wang, Virangika K. Wimalasena et al. · Cancer Discovery · 2021 · 149 citations · Full text

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma

Yan Song, Paul M.C. Park, Lei Wu et al. · Leukemia · 2019 · 42 citations

, , +6

Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma

Hiroto Ohguchi, Paul M.C. Park, Tingjian Wang et al. · Blood Cancer Discovery · 2021 · 39 citations · Full text

Development of Dimethylisoxazole-Attached Imidazo[1,2-<i>a</i>]pyridines as Potent and Selective CBP/P300 Inhibitors

Alex Muthengi, Virangika K. Wimalasena, Hailemichael O. Yosief et al. · Journal of Medicinal Chemistry · 2021 · 30 citations · Full text

Colicin E1 opens its hinge to plug TolC

S. Jimmy Budiardjo, Jacqueline J. Stevens, Anna L. Calkins et al. · eLife · 2022 · 26 citations · Full text

Rows per page

1–5 of 5